2024-01-30 01:41:02 ET
Summary
- Neuronetics' stock has rebounded significantly over the past 3 months, although this has been driven more by investor sentiment than company fundamentals.
- TMS remains underutilized given its efficacy, which should lead to greater adoption in coming years, even if growth is at a relatively modest pace.
- STIM is still a long way from profitability. Something the company must rectify in the coming quarters.
- Modest growth and a gradual improvement in profitability will probably not be sufficient to lift the share price higher.
...
Read the full article on Seeking Alpha
For further details see:
Neuronetics: Modest Improvements Are Not Enough